Moossavi Shahriar, Tuttle Audrey B, Vachharajani Tushar J, Plonk George, Bettmann Michael A, Majekodunmi Omotayo, Russell Gregory B, Regan John D, Freedman Barry I
Department of Internal Medicine/Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, U.S.A.
Hemodial Int. 2008 Jan;12(1):80-4. doi: 10.1111/j.1542-4758.2008.00245.x.
The need for reliable, long-term hemodialysis vascular access remains critical. To determine the long-term outcomes of transposed basilic vein arteriovenous fistulae (BVT) and their comparability with other vascular accesses, we determined retrospectively the primary and secondary patency rates in 58 BVT and in a total of 58 arteriovenous fistulae (AVF) and arteriovenous grafts (AVG) at a single center. Fifty-eight BVT were placed in 57 individuals, 69% after prior vascular access failure. Ten BVT failed before initial use and 2 patients expired with functioning accesses before dialysis initiation. In all 58 BVT, 46.8+/-10.8% functioned at 3 years, with median survival 30.8 months. Limiting analyses to the 46 BVT that were ultimately accessed, 3-year primary and secondary patency rates were 38.3+/-7.7% and 56.5+/-12.6%, respectively. Lower ejection fraction (p=0.054) and greater numbers of prior permanent dialysis catheters (p=0.005) were present in those with failed BVT. Compared with AVF, BVT had similar 3-year primary and secondary patency rates. The secondary patency rate was significantly better for BVT vs. AVG over the observation period; at 3 years, the rates were 56.5+/-12.6% vs. 9.1+/-6.0% (p=0.002), respectively. Basilic vein arteriovenous fistulae are valuable hemodialysis accesses. Although nearly 20% of newly placed BVT will not function before first use, those that are functional have median survivals exceeding 6 years, and 38% will not require intervention within 3 years of initial use.
对可靠的长期血液透析血管通路的需求仍然至关重要。为了确定转位贵要静脉动静脉内瘘(BVT)的长期结果及其与其他血管通路的可比性,我们在单一中心回顾性地确定了58例BVT以及总共58例动静脉内瘘(AVF)和动静脉移植物(AVG)的初级和次级通畅率。58例BVT植入了57例个体,69%是在先前血管通路失败后进行的。10例BVT在初次使用前失败,2例患者在透析开始前因功能正常的通路而死亡。在所有58例BVT中,46.8±10.8%在3年时仍在发挥功能,中位生存期为30.8个月。将分析限于最终使用的46例BVT,3年的初级和次级通畅率分别为38.3±7.7%和56.5±12.6%。BVT失败的患者中存在较低的射血分数(p = 0.054)和更多的先前永久性透析导管(p = 0.005)。与AVF相比,BVT的3年初级和次级通畅率相似。在观察期内,BVT的次级通畅率明显优于AVG;在3年时,通畅率分别为56.5±12.6%和9.1±6.0%(p = 0.002)。贵要静脉动静脉内瘘是有价值的血液透析通路。尽管近20%新植入的BVT在首次使用前无法发挥功能,但那些功能正常的BVT中位生存期超过6年,38%在初次使用后3年内不需要干预。